Mark Locke - 15 Sep 2026 Form 4 Insider Report for Genius Sports Ltd (GENI)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: GENI
Reported as of: 15 Sep 2026
Net transaction value: -$5,255,568
SEC form: 4
Accepted by SEC: 17 Sep 2026, 20:00:07 UTC
Prior SEC filing: 24 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Duncanson, Attorney-in Fact

Key filing fact

Mark Locke filed Form 4 for Genius Sports Ltd (GENI) on 17 Sep 2026.

Key facts

This page summarizes Mark Locke's Form 4 filing for Genius Sports Ltd (GENI).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Sep 2026, 20:00.

Change

Previous filing in this sequence was filed on 24 Mar 2026.
Current net transaction value: -$5,255,568.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001859559 Primary reporting owner

Locke Mark

Relationship: Chief Executive Officer, Director
Address: C/O GENIUS SPORTS LTD, SEYMOUR MEWS HOUSE, 26-37 SEYMOUR MEWS, LONDON, UNITED KINGDOM
Signature: /s/ Carolyn Duncanson, Attorney-in Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GENI transaction

Ordinary Shares

Sale

Transaction value: $3,139,275
Shares: -477,449
Change %: -2.4%
Price: $6.58
Shares after: 19,697,767
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

GENI transaction

Ordinary Shares

Sale

Transaction value: $1,789,243
Shares: -272,551
Change %: -1.4%
Price: $6.56
Shares after: 19,425,216
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F2

GENI transaction

Ordinary Shares

Sale

Transaction value: $327,050
Shares: -50,000
Change %: -0.26%
Price: $6.54
Shares after: 19,375,216
Date: 17 Sep 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GENI transaction Derivative

Call Option (obligation to sell)

Sale

Transaction value
Shares: -1
Change %: -50%
Price
Shares after: 1
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,400,000
Exercise price: $10.20
Footnotes: F3

GENI transaction Derivative

Put Option (right to sell)

Purchase

Transaction value
Shares: +1
Change %
Price
Shares after: 1
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,400,000
Exercise price: $5.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4663 to $6.7219. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4998 to $6.6795. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

On September 15, 2026 the Reporting Person entered into a 'zero cost collar' arrangement (the "Transactions") pursuant to which they wrote European call options and purchased American put options over an aggregate 4,400,000 Ordinary Shares. Only one of the options can be in the money on the expiration date, at which time the in-the-money options will be exercised, and the other options will expire. If neither the put options nor the call options are in the money on the expiration date, both will expire. The Transactions will be settled in cash unless the Reporting Person elects physical settlement. The Transactions are 'zero cost collars' in which no premium was exchanged for either the call options or the put options.